- Home
- KWY vs CATX Comparison
KWY vs CATX Comparison
Compare KWY & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KWY | CATX |
|---|---|---|
| Founded | N/A | 1983 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.1M | 341.0M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KWY | CATX |
|---|---|---|
| Price | $10.42 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 65.1K | ★ 1.1M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,996,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.42 | N/A |
| 52 Week Low | $8.41 | $1.96 |
| 52 Week High | $11.36 | $6.16 |
Technical Indicators
Market Signals| Indicator | KWY | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 57.25 |
| Support Level | $9.75 | $2.82 |
| Resistance Level | $10.77 | $3.78 |
| Average True Range (ATR) | 0.44 | 0.18 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 98.73 | 65.62 |
Price Performance
Historical ComparisonAbout KWY Kingsway Corporation Common Stock
Kingsway Corp is a U.S.-based company employing the Search Fund model to acquire and build great businesses. The company owns and operates a collection of B2B and B2C services companies that are asset-light, growing, profitable, and that have recurring revenues. It seeks to compound long-term shareholder value on a per share basis via its decentralized management model, its talented team of operators, and its tax-advantaged corporate structure.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.